Sepimostat

Cat. No.: HY-136299

CAS No.: 103926-64-3

Molecular Formula: $C_{21}H_{19}N_5O_2$

Molecular Weight: 373.41

Target: iGluR

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 6.25 mg/mL (16.74 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.6780 mL	13.3901 mL	26.7802 mL
	5 mM	0.5356 mL	2.6780 mL	5.3560 mL
	10 mM	0.2678 mL	1.3390 mL	2.6780 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Sepimostat (FUT-187 free base) exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit. Sepimostat inhibits the Ifenprodil binding with a K_i value of 27.7 μM[1].

In Vivo

Sepimostat (1 to 100 nmol/eye, intravitreal injection) exhibits significant neuroprotective effect[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague Dawley rats weighing 150-300 g[1].
Dosage:	Intravitreal injection.
Administration:	1 to 100 nmol/eye.
Result:	Exhibited neuroprotective effects significantly.

CUSTOMER VALIDATION

- Eur J Pharmacol. 2022 Nov 17;175394.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Masahiro Fuwa, et al. Nafamostat and Sepimostat Identified as Novel Neuroprotective Agents via NR2B N-methyl-D-aspartate Receptor Antagonism Using a Rat Retinal Excitotoxicity Model. Sci Rep. 2019 Dec 31;9(1):20409.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA